Current Neurology and Neuroscience Reports

, Volume 10, Issue 5, pp 359–366 | Cite as

Hormonal Influences on Cognition and Risk for Alzheimer’s Disease

  • Sarah C. JanickiEmail author
  • Nicole Schupf


Research increasingly suggests that changes in estrogen levels during aging may increase the risk of Alzheimer’s disease, the most common type of dementia. This update reviews the newest information about estrogen and cognitive aging, including information regarding the role of bioavailable estrogen in older women and men, use of selective estrogen receptor modulators to improve cognition, and studies of genetic risk factors to elucidate the effects of endogenous estrogen on aging and cognition. Future trials are needed to determine whether alternate timing, dosage, formulation, or method of administration of hormone replacement can reduce the risk of dementia.


Alzheimer’s Disease Dementia Estrogen Hormone Replacement Therapy Genetics 



Dr. Janicki receives support from the Charles L. and Ann Lee Saunders Brown Fellowship fund and National Institutes of Health (NIH) grant 5 T32 MH2004 Clinical Research Training in Geriatric Neuropsychiatry.

Dr. Schupf receives support from NIH grants #R01AG014673 (principal investigator [PI]), #P01HD035897 (coinvestigator [Co-I]), #P01AG07232 (Co-I), #R01AG028786 (Co-I), #U01 AG023749 (Co-I), #P50 AG08702 (Co-I), #R01AG007370 (Co-I), #R21CA125461 (Co-I), #R01AG036040 (Co-I), and #AG034189 (Co-I) and from Alzheimer’s Association grants #IIRG-08-90655 (PI) and #IIRG-08-92010 (Co-I).


Dr. Schupf is a consultant to Janssen Alzheimer Immunotherapy. No other potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Goodman Y, Bruce AJ, Cheng B, Mattson MP: Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem 1996, 66:1836–1844.CrossRefPubMedGoogle Scholar
  2. 2.
    Toran-Allerand CD, Miranda RC, Bentham WD, et al.: Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A 1992, 89:4668–4672.CrossRefPubMedGoogle Scholar
  3. 3.
    Luine VN: Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985, 89:484–490.CrossRefPubMedGoogle Scholar
  4. 4.
    Behl C, Widmann M, Trapp T, Holsboer F: 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 1995, 216:473–482.CrossRefPubMedGoogle Scholar
  5. 5.
    Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE: Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem 1994, 269:13065–13068.PubMedGoogle Scholar
  6. 6.
    Andersen K, Launer LJ, Dewey ME, et al.: Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. EURODEM Incidence Research Group. Neurology 1999, 53:1992–1997.PubMedGoogle Scholar
  7. 7.
    Fratiglioni L, Viitanen M, von Strauss E, et al.: Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 1997, 48:132–138.PubMedGoogle Scholar
  8. 8.
    Ganguli M, Dodge HH, Chen P, et al.: Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. Neurology 2000, 54:1109–1116.PubMedGoogle Scholar
  9. 9.
    Rocca WA, Cha RH, Waring SC, Kokmen E: Incidence of dementia and Alzheimer's disease: a reanalysis of data from Rochester, Minnesota, 1975–1984. Am J Epidemiol 1998, 148:51–62.PubMedGoogle Scholar
  10. 10.
    Bachman DL, Wolf PA, Linn RT, et al.: Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology 1993, 43:515–519.PubMedGoogle Scholar
  11. 11.
    Kawas C, Gray S, Brookmeyer R, et al.: Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 2000, 54:2072–2077.PubMedGoogle Scholar
  12. 12.
    Hebert LE, Scherr PA, Beckett LA, et al.: Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995, 273:1354–1359.CrossRefPubMedGoogle Scholar
  13. 13.
    Kukull WA, Higdon R, Bowen JD, et al.: Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002, 59:1737–1746.CrossRefPubMedGoogle Scholar
  14. 14.
    Barrett-Connor E, von Muhlen D, Laughlin GA, Kripke A: Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 1999, 47:685–691.PubMedGoogle Scholar
  15. 15.
    Jacobs DM, Tang MX, Stern Y, et al.: Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998, 50:368–373.PubMedGoogle Scholar
  16. 16.
    Paganini-Hill A, Henderson VW: Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994, 140:256–261.PubMedGoogle Scholar
  17. 17.
    Tang MX, Jacobs D, Stern Y, et al.: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996, 348:429–432.CrossRefPubMedGoogle Scholar
  18. 18.
    Yaffe K, Lui LY, Grady D, et al.: Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet 2000, 356:708–712.CrossRefPubMedGoogle Scholar
  19. 19.
    Zandi PP, Carlson MC, Plassman BL, et al.: Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002, 288:2123–2129.CrossRefPubMedGoogle Scholar
  20. 20.
    • Henderson VW: Aging, estrogens and episodic memory in women. Cogn Behav Neurol 2009, 22:205–214. This is a useful review of the relationships between estrogen exposure and memory in women, with a discussion of the critical-window hypothesis in estrogen supplementation. CrossRefPubMedGoogle Scholar
  21. 21.
    Resnick SM, Henderson VW: Hormone therapy and risk of Alzheimer disease: a critical time. JAMA 2002, 288:2170–2172.CrossRefPubMedGoogle Scholar
  22. 22.
    Joffe H, Hall JE, Gruber S, et al.: Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause 2006, 13:411–422.CrossRefPubMedGoogle Scholar
  23. 23.
    Phillips SM, Sherwin BB: Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992, 17:485–495.CrossRefPubMedGoogle Scholar
  24. 24.
    Sherwin BB: Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988, 13:345–357.CrossRefPubMedGoogle Scholar
  25. 25.
    Almeida OP, Lautenschlager NT, Vasikaran S, et al.: A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiol Aging 2006, 27:141–149.CrossRefPubMedGoogle Scholar
  26. 26.
    Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C: Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology 2005, 30:309–315.CrossRefPubMedGoogle Scholar
  27. 27.
    Wolf OT, Kudielka BM, Hellhammer DH, et al.: Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: verbal memory changes are associated with the treatment induced estradiol levels. Psychoneuroendocrinology 1999, 24:727–741.CrossRefPubMedGoogle Scholar
  28. 28.
    Maki PM, Gast MJ, Vieweg AJ, et al.: Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology 2007, 69:1322–1330.CrossRefPubMedGoogle Scholar
  29. 29.
    Linzmayer L, Semlitsch HV, Saletu B, et al.: Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Arzneimittelforschung 2001, 51:238–245.PubMedGoogle Scholar
  30. 30.
    Pefanco MA, Kenny AM, Kaplan RF, et al.: The effect of 3-year treatment with 0.25 mg/day of micronized 17beta-estradiol on cognitive function in older postmenopausal women. J Am Geriatr Soc 2007, 55:426–431.CrossRefPubMedGoogle Scholar
  31. 31.
    Resnick SM, Maki PM, Rapp SR, et al.: Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006, 91:1802–1810.CrossRefPubMedGoogle Scholar
  32. 32.
    Grady D, Yaffe K, Kristof M, et al.: Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/Progestin Replacement Study. Am J Med 2002, 113:543–548.CrossRefPubMedGoogle Scholar
  33. 33.
    Shumaker SA, Reboussin BA, Espeland MA, et al.: The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 1998, 19:604–621.CrossRefPubMedGoogle Scholar
  34. 34.
    Shumaker SA, Legault C, Rapp SR, et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2651–2662.CrossRefPubMedGoogle Scholar
  35. 35.
    Shumaker SA, Legault C, Kuller L, et al.: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004, 291:2947–2958.CrossRefPubMedGoogle Scholar
  36. 36.
    Nilsen J, Brinton RD: Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci U S A 2003, 100:10506–10511.CrossRefPubMedGoogle Scholar
  37. 37.
    • Sano M, Jacobs D, Andrews H, et al.: A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics. Clin Trials 2008, 5:523–533. This article describes the design of the PREPARE trial. Although the study results are not yet published, it is anticipated they will address whether there are lasting or delayed effects of HRT on cognition after treatment cessation. CrossRefPubMedGoogle Scholar
  38. 38.
    •• Miller VM, Black DM, Brinton EA, et al.: Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009, 2:228–239. This article discusses the design and rationale of KEEPS, which will investigate the critical-timing hypothesis of estrogen supplementation by evaluating the effects of HRT on a younger female population. CrossRefPubMedGoogle Scholar
  39. 39.
    Early vs Late Intervention Trial with Estradiol (ELITE). Available at Accessed March 2010.
  40. 40.
    Yaffe K, Grady D, Pressman A, Cummings S: Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women . J Am Geriatr Soc 1998, 46:816–821.PubMedGoogle Scholar
  41. 41.
    Lebrun CE, van der Schouw YT, de Jong FH, et al.: Endogenous oestrogens are related to cognition in healthy elderly women. Clin Endocrinol (Oxf) 2005, 63:50–55.CrossRefGoogle Scholar
  42. 42.
    Schupf N, Pang D, Patel BN, et al.: Onset of dementia is associated with age at menopause in women with Down's syndrome. Ann Neurol 2003, 54:433–438.CrossRefPubMedGoogle Scholar
  43. 43.
    Hoskin EK, Tang MX, Manly JJ, Mayeux R: Elevated sex-hormone binding globulin in elderly women with Alzheimer's disease. Neurobiol Aging 2004, 25:141–147.CrossRefPubMedGoogle Scholar
  44. 44.
    Schupf N, Winsten S, Patel B, et al.: Bioavailable estradiol and age at onset of Alzheimer's disease in postmenopausal women with Down syndrome. Neurosci Lett 2006, 406:298–302.CrossRefPubMedGoogle Scholar
  45. 45.
    Geerlings MI, Launer LJ, de Jong FH, et al.: Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann Neurol 2003, 53:607–615.CrossRefPubMedGoogle Scholar
  46. 46.
    Yaffe K, Barnes D, Lindquist K, et al.: Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol Aging 2007, 28:171–178.CrossRefPubMedGoogle Scholar
  47. 47.
    Carlson LE, Sherwin BB: Higher levels of plasma estradiol and testosterone in healthy elderly men compared with age-matched women may protect aspects of explicit memory. Menopause 2000, 7:168–177.CrossRefPubMedGoogle Scholar
  48. 48.
    Young LA, Neiss MB, Samuels MH, et al.: Cognition is not modified by large but temporary changes in sex hormones in men. J Clin Endocrinol Metab 2010, 95:280–288.CrossRefPubMedGoogle Scholar
  49. 49.
    Kampen DL, Sherwin BB: Estradiol is related to visual memory in healthy young men. Behav Neurosci 1996, 110:613–617.CrossRefPubMedGoogle Scholar
  50. 50.
    Hogervorst E, De Jager C, Budge M, Smith AD: Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women. Psychoneuroendocrinology 2004, 29:405–421.CrossRefPubMedGoogle Scholar
  51. 51.
    Senanarong V, Vannasaeng S, Poungvarin N, et al.: Endogenous estradiol in elderly individuals: cognitive and noncognitive associations. Arch Neurol 2002, 59:385–389.CrossRefPubMedGoogle Scholar
  52. 52.
    Wolf OT, Kirschbaum C: Endogenous estradiol and testosterone levels are associated with cognitive performance in older women and men . Horm Behav 2002, 41:259–266.CrossRefPubMedGoogle Scholar
  53. 53.
    Lessov-Schlaggar CN, Reed T, Swan GE, et al.: Association of sex steroid hormones with brain morphology and cognition in healthy elderly men. Neurology 2005, 65:1591–1596.CrossRefPubMedGoogle Scholar
  54. 54.
    Matousek RH, Sherwin BB: A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. Psychoneuroendocrinology 2010, 35:215–225.CrossRefPubMedGoogle Scholar
  55. 55.
    Geerlings MI, Strozyk D, Masaki K, et al.: Endogenous sex hormones, cognitive decline, and future dementia in old men. Ann Neurol 2006, 60:346–355.CrossRefPubMedGoogle Scholar
  56. 56.
    Cherrier MM, Matsumoto AM, Amory JK, et al.: Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. Psychoneuroendocrinology 2007, 32:72–79.CrossRefPubMedGoogle Scholar
  57. 57.
    Beer TM, Bland LB, Bussiere JR, et al.: Testosterone loss and estradiol administration modify memory in men. J Urol 2006, 175:130–135.CrossRefPubMedGoogle Scholar
  58. 58.
    Kenny AM, Bellantonio S, Gruman CA, et al.: Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2002, 57:M321–M325.PubMedGoogle Scholar
  59. 59.
    Taxel P, Stevens MC, Trahiotis M, et al.: The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer. J Am Geriatr Soc 2004, 52:269–273.CrossRefPubMedGoogle Scholar
  60. 60.
    Janowsky JS, Chavez B, Orwoll E: Sex steroids modify working memory. J Cogn Neurosci 2000, 12:407–414.CrossRefPubMedGoogle Scholar
  61. 61.
    Cherrier MM, Matsumoto AM, Amory JK, et al.: The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology 2005, 64:290–296.CrossRefPubMedGoogle Scholar
  62. 62.
    Sherwin BB, Chertkow H, Schipper H, Nasreddine Z: A randomized controlled trial of estrogen treatment in men with mild cognitive impairment. Neurobiol Aging (Epub ahead of print). Google Scholar
  63. 63.
    Yaffe K, Lui LY, Zmuda J, Cauley J: Sex hormones and cognitive function in older men. J Am Geriatr Soc 2002, 50:707–712.CrossRefPubMedGoogle Scholar
  64. 64.
    Yaffe K, Krueger K, Cummings SR, et al.: Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005, 162:683–690.CrossRefPubMedGoogle Scholar
  65. 65.
    Legault C, Maki PM, Resnick SM, et al.: Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol 2009, 27:5144–5152.CrossRefPubMedGoogle Scholar
  66. 66.
    •• Espeland MA, Shumaker SA, Limacher M, et al.: Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health (Larchmt) 2010, 19:371–379. This secondary analysis study raises the possibility that both tamoxifen and raloxifene adversely affect cognitive function in older women; however, the magnitude of the effect is small and the long-term consequences are unknown.CrossRefGoogle Scholar
  67. 67.
    Brandi ML, Becherini L, Gennari L, et al.: Association of the estrogen receptor alpha gene polymorphisms with sporadic Alzheimer's disease. Biochem Biophys Res Commun 1999, 265:335–338.CrossRefPubMedGoogle Scholar
  68. 68.
    Corbo RM, Gambina G, Ruggeri M, Scacchi R: Association of estrogen receptor alpha (ESR1) PvuII and XbaI polymorphisms with sporadic Alzheimer's disease and their effect on apolipoprotein E concentrations. Dement Geriatr Cogn Disord 2006, 22:67–72.CrossRefPubMedGoogle Scholar
  69. 69.
    Isoe-Wada K, Maeda M, Yong J, et al.: Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia. Eur J Neurol 1999, 6:431–435.CrossRefPubMedGoogle Scholar
  70. 70.
    Ji Y, Urakami K, Wada-Isoe K, et al.: Estrogen receptor gene polymorphisms in patients with Alzheimer's disease, vascular dementia and alcohol-associated dementia. Dement Geriatr Cogn Disord 2000, 11:119–122.CrossRefPubMedGoogle Scholar
  71. 71.
    Schupf N, Lee JH, Wei M, et al.: Estrogen receptor-alpha variants increase risk of Alzheimer’s disease in women with Down syndrome. Dement Geriatr Cogn Disord 2008, 25:476–482.CrossRefPubMedGoogle Scholar
  72. 72.
    Pirskanen M, Hiltunen M, Mannermaa A, et al.: Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women. Eur J Hum Genet 2005, 13:1000–1006.CrossRefPubMedGoogle Scholar
  73. 73.
    Forsell C, Enmark E, Axelman K, et al.: Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer's disease. Eur J Hum Genet 2001, 9:802–804.CrossRefPubMedGoogle Scholar
  74. 74.
    • Yaffe K, Lindquist K, Sen S, et al.: Estrogen receptor genotype and risk of cognitive impairment in elders: findings from the Health ABC study. Neurobiol Aging 2009, 30:607–614. This study’s findings that several SNPs in the ESR1 and ESR2 genes were associated with risk of developing cognitive impairment suggest that ER genetic variants might play a role in cognitive aging.CrossRefPubMedGoogle Scholar
  75. 75.
    Huang R, Poduslo SE: CYP19 haplotypes increase risk for Alzheimer's disease. J Med Genet 2006, 43:e42.CrossRefPubMedGoogle Scholar
  76. 76.
    Iivonen S, Corder E, Lehtovirta M, et al.: Polymorphisms in the CYP19 gene confer increased risk for Alzheimer disease. Neurology 2004, 62:1170–1176.PubMedGoogle Scholar
  77. 77.
    Butler HT, Warden DR, Hogervorst E, et al.: Association of the aromatase gene with Alzheimer's disease in women. Neurosci Lett 2010, 468:202–206.CrossRefPubMedGoogle Scholar
  78. 78.
    Corbo RM, Gambina G, Ulizzi L, et al.: Genetic variation of CYP19 (aromatase) gene influences age at onset of Alzheimer’s disease in women. Dement Geriatr Cogn Disord 2009, 27:513–518.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.G. H. Sergievsky CenterColumbia University Medical CenterNew YorkUSA

Personalised recommendations